Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07603375 · ClinicalTrials.gov registry record · Phase 2
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
A Phase 2 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07603375 is a Phase 2 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 60 participants.
The verdict
NCT07603375, a Phase 2 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
Interventions
- DRUG FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2034-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07603375
The ClinicalTrials.gov registry entry for NCT07603375 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) is the first listed.
NCT07603375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07603375 about?
NCT07603375 is a clinical study titled "Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma". The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
What is the current status of trial NCT07603375?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-08-01. Estimated completion is 2034-02.
What interventions are being tested in trial NCT07603375?
The interventions under investigation include: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) (DRUG).
Who is sponsoring clinical trial NCT07603375?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.